

A Lack of Diversity of Patient Representation in Medicine Development

Authors: Graham McClelland, Arjin Koc & Fatima Auwal.

Centre for Pharmaceutical Medicine Research (CPMR), Institute of Pharmaceutical Science, King's College London, London SE1 9NH


Email: graham.mcclelland@kcl.ac.uk

INGS College DNDON

<u>ک</u>




In recent years, regulatory authorities, pharmaceutical companies and other clinical trial Sponsors have shifted to a more patient-centric approach, incorporating their input into medicine development decisions [1].



Patient Advocates (PAs) play an essential role in representing that patient voice and their wishes.

BACKGROUND



There remains a significant gap in research concerning the diversity of PAs and the extent to which they can truly represent the patient populations they are meant to represent.



This study has examined the representativeness of selfidentified PAs in medicine development against the known demographics.

To what extent do self-identified patient advocates on the professional network LinkedIn reflect the demographic and clinical characteristics of the disease populations they represent in the UK, compared to national disease demographics?

METHOD

Data were collected from LinkedIn profiles using specific inclusion criteria between May and August 2024.



This research employed descriptive observational methods to assess the demographic representativeness of self-identified > PAs based in the UK.

in




The collected data were classified according to age, sex, ethnicity, and educational background. A comparative analysis was conducted between the demographics of PAs and the known demographics of the patient populations they represent.



The methodology relied on visual assessments of publicly available information, acknowledging limitations in data accessibility and potential observer bias, particularly in the classification of demographic characteristics.

RESULTS






Figure 1: Distribution of Sex Demographics among PAs with (n=174, after exclusion of "unknown" profiles n=30)

Figure 2: Distribution of Age Demographics among PAs with (n=170, after exclusion of "unknown" profiles n=34)




Figure 3: Distribution of Ethnicity **Demographics among PAs with** (n=157, after exclusion of "unknown" profiles n=47)




Figure 4: Distribution of Educational Background among PAs with (n=134, after exclusion of "unknown" profiles n=70)


CONCLUSION

FUTURE DIRECTION



Inequiities and a lack of diversity among self-identified PAs in the UK.

Whilst this research was limited to just the LinkedIn database, the results do indicate that there needs to be actions to ensure that there is a wider patient representation in the provision of input into medicine development decisionmaking.



References 1. Auwal F, Copeland C, Clark EJ, Naraynassamy C, McClelland GR. A review of models of patient engagement in the development and lifecycle management of medicines. Drug Discovery Today. 2023; 89(9):103702-1037210. doi.org/10.1016/j.drudis.2023.103702